All In Biotech

Drug Trial Radar · NCT03207672

Study of E7389 Liposomal Formulation in Participants With Solid Tumor

An Open-label Phase 1 Study of E7389 Liposomal Formulation in Subjects With Solid Tumor

Last checked: Nov 19, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

140

Planned (sponsor's estimate)

Start

Aug 18, 2017

Primary completion

Jul 19, 2018

Study completion Mar 31, 2027

Sponsor

Lead sponsor
Eisai Co., Ltd.Eisai
Sponsor type
Industry
First posted
Jul 5, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The maximum tolerated dose (MTD) of E7389 liposomal formulation (E7389-LF) will be determined in the dose escalation part. Safety, pharmacokinetics (PK) and efficacy will be assessed using treatment regimen evaluated in dose escalation part in participants with breast cancer (up to 3 prior regimens of chemotherapy) in the expansion part 1 and in participants with adenoid cystic carcinoma (ACC), gastric cancer (GC), esophageal cancer (EGC), small cell lung cancer (SCLC) and breast cancer (with no prior regimens of chemotherapy) in the expansion part 2, 3, 4, 5 and 6 respectively.

Conditions

  • Solid Tumor

Interventions

  • E7389-LFDrug

    intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum tolerated dose (MTD) of E7389 liposomal formulation (E7389-LF)Time frame: Cycle 1 (21 days): Schedule 1; Cycle 1 (28 days): Schedule 2

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Eisai Trial Site 12

    Fukuoka, Japan

  • Eisai Trial Site 11

    Kyoto, Japan

  • Eisai Trial Site 2

    Osaka, Japan

  • Eisai Trial Site 3

    Kashiwa, Chiba, Japan

  • Eisai Trial Site 5

    Sapporo, Hokkaido, Japan

  • Eisai Trial Site 8

    Nishinomiya, Hyōgo, Japan

  • Eisai Trial Site 6

    Yokohama, Kanagawa, Japan

  • Eisai Trial Site 10

    Hidaka, Saitama, Japan

  • Eisai Trial Site 9

    Bunkyo-ku, Tokyo, Japan

  • Eisai Trial Site 1

    Chuo-ku, Tokyo, Japan

  • Eisai Trial Site 4

    Koto-ku, Tokyo, Japan

  • Eisai Trial Site 7

    Shinjuku-ku, Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.